FinanceDoc

Everyone is focused on Eli Lilly right now… but as a doctor, I think Novo Nordisk is quietly setting up a comeback that most people are missing. By the end of this thread, you’ll see why 🧵 $LLY $NVO

@harjaim You’d have to work for a very long time…

@FinanceDocUK You can always clear the balance in your 50s from your invested corpus. That is my exact strategy: let the capital compound for as long as possible, knowing I can always pay off the mortgage instantly from my portfolio if the need arises

Good morning gang ☕️ You’ve already: ✅ Paid this month’s mortgage ✅ Made this month’s investments Then you pick up an extra shift and earn £300. What are you doing with it? A) Mortgage overpayment 🏠 B) Invest it 📈 Why?

@AshyCompounds Let’s do it brother!

Good morning all and happy Friyay. Let's finish the week strong 💪. Have a good one all!

@harjaim I don’t want to be in my 50s paying off my mortgage In my late 40s I don’t know if I’ll have the same energy to continue working as this same rate A part of me wants to be debt free, whilst also investing, fairly quickly!

@FinanceDocUK I’ll just invest every extra penny. Mortgage is generally the cheapest money we’ll ever get, unless you’re on a newer or variable rate well over 5%. Otherwise, let it compound!

@BRCTrades99 It’s the REDEFINE 4 trial Novo arranged a trial - H2H vs LLY It’s next gen med vs LLYs Tzp Results: ⬇️

@FinanceDocUK Thanks mate! I’ve read about it briefly but would need to look into more before forming too much of an opinion.

Morning all! Today’s view. $NVO infographic coming later this evening 🚀 What’s the weather like back in the UK?

@PinguStacks Such a low rate, wow! The peace of knowing you’re debt free and won’t have to work till your 50s to pay it off - is invaluable however 😅

@FinanceDocUK Invest, you know me 😂 Mortgage is at 2.59% right now, it's a no brainer... would even do better in a HYSA than overpaying 🫡

@SOUKCOMMUNITY @EllaGraceEdge_ The bigger picture 📈

a volatile week - but if in doubt, zoom out

@robunhedged @Idomeneus_OG Apply the same logic to LLY: >Imagine Reta failed to show superiority versus Wegovy injection >In a trial made by LLY Would you still be advocating for Reta? It’s important to be realistic, you’d naturally think LLYs next gen flopped.

I agree, tolerability is likely a bigger issue for people than headline weight loss. That’s actually the point I’m getting at really. In a chronic obesity mass-market treatment, the best overall profile may matter more than max weight loss. I think oral wegovy is looking really strong there, which is why I don't think CagriSema needs to carry the thesis on the stock price recovery.

$NVO I am not convinced CagriSema matters quite as much as certain bears would have you believe. Yes, Novo needs next gen drugs. Yes, CagriSema was supposed to help defend the franchise against $LLY. But I think the market is over-weighting its significance. Many patients using obesity drugs may not need the most aggressive weight-loss option available. For a mass-market obesity treatment, I don’t think the winner will simply be the drug with the highest headline weight-loss number. It is probably the drug with the best mix of: • enough weight loss • safety • tolerability • convenience • adherence • access • long-term outcomes That is why Wegovy still matters. That is why oral Wegovy may matter even more. A pill that delivers “good enough” weight loss with strong uptake will be more commercially important than a stronger injectable aimed at patients needing deeper weight loss. CagriSema is still useful. It gives Novo another pathway, another patient segment, and one possible bridge across the semaglutide cliff. But I don’t think Novo’s entire future depends on it becoming the undisputed obesity king. The bigger question is whether Novo can build a portfolio of: Wegovy injection Oral Wegovy Higher-dose Wegovy CagriSema Amycretin new indications for existing pipeline future licensed assets If that portfolio holds together, CagriSema does not need to carry the whole Novo thesis. It just needs to be one useful piece of the bridge.

Hey Rob, great post - thank you! I’m also a Novo investor, but I’ve evaluated this in my previous post which I’ve linked below. I agree, WL isn’t the only factor to determine a drug’s success. Factors like tolerability & safety, matter too. Which is actually why I think Wegovy pill is far superior than foundayo - we both agree here 👌🏼 I disagree however on your take with CS. From my perspective, as a doctor, what would be my rationale for prescribing CS? I can’t blindly prescribe it. - if my patients wanted oral pills for convenience, I would prescribe Wegovy pill within a heartbeat. - if my patients wanted an injectable, because they want greater rate of WL; I’d prescribe Tzp given it’s superior to CS (as Novo has proven, via its own clinical trial failure) Does that make sense? Medically speaking, why would I choose CS over Tzp? It’s a next gen drug, expectations are that it SHOULD be more superior than current gen meds. It’s failed. Across competitors and its own current gen pipeline too.

@kahnfessions Yes, I have one! Group of likeminded investors enticed by the prospect of modern medicine !! Let me know if you’re interested :)

is anyone in good health tech group chats

@wave3trades HIMS have the infrastructure set to literally propel. >Peptides + branded drugs >Upscaled via Eucalyptus to international markets

You buy $HIMS at $28 Peptides are reclassified $HIMS sells peptides worldwide $100b market cap+

The ADA diabetes conference kicks off this weekend in New Orleans, and obesity and diabetes investors will have plenty to watch. According to Jyske Bank, the main focus for $NVO will be: • CagriSema in obesity and type 2 diabetes following its disappointing head-to-head performance versus $LLY Zepbound • Zenagamtide in type 2 diabetes • UBT251 in obesity Jyske Bank will also be watching new data from Lilly’s retatrutide, which recently delivered 28.3% weight loss at the highest dose. Other companies presenting data include $PFE with its monthly GLP-1 candidate berobenatid and Zealand Pharma/ Roche with petrelintide. Novo will host its own ADA investor event on June 7 to discuss the data and broader pipeline developments. #stocks #Investing

Sounds good!! Plenty of amazing healthcare companies >Some more established than others, generating revenue constantly >Some more “growth stock” with massive potential pending trial results >Some just completely undervalued currently I love exploring each of the above on my page and glad it provided you value!!

90 total holdings mate hahahaha 😂 I genuinely love investing... when there's 10s of thousands of stocks out there... narrowing down to 90 was the best I could do 😂 I spend hours looking at stocks so naturally I pick up ideas here and there and feel like they deserve a spot, they're all deliberately allocated into certain themes, generally 10 per theme for most areas 👍 You've actually inspired me to potentially make a new thematic pie specifically for biotech/health are as currently I have $RXRX in Frontier innovation, $TEM in SaaS and $NVS $LLY $JNJ in my broad market defensive base. But I have no cash to bring it up to a worthwhile position size, and it would take some fiddling with swapping stocks around to balance everything how I want it haha.

Morning all 🫡🐧 Looking like a sea of red today at LSE market open for me - let's see how the rest of the day unfolds when US opens later on today. How's everyone else feeling today, any moves being made? 👀

@arthritisfinger Owning both 🙃🤝

@FinanceDocUK Great for $HIMS

*** NOVO NORDISK 🤝 UNITED KINGDOM *** ------------------------------------------------------ Ladies & gentlemen, this might be one of the greatest moves the NHS pulls off. Policy makers internationally are waking up to the benefits of oral semaglutide. U&E ✅ UK ⌛️ $NVO

@fdzmurillo @VSchwazkopf @Matkinvest I also want to caveat this by mentioning? ASCO didn’t specifically find cancer benefits for semaglutide. It was for GLP1s overall, which includes LLYs drugs also.

Two things misaligned in the current debate: 1. Wegovy HD 7.2mg already delivers ≥25% weight loss to 31.2% of patients on label. That's the benchmark, today, approved, in market. 2. Retatrutide in 2028 is solving last decade's problem. By then the obesity conversation will have shifted to preventive cardiometabolic, longevity, multi-organ outcomes. The relevant target patient won't be BMI 35 acute obesity — it'll be 50-year-old metabolic risk seeking 20-year disease modification. Molecule with most outcomes data wins the platform game. SELECT, FLOW, ESSENCE, SOUL, ASCO 2026 — all on semaglutide. The horizon-mismatched debate is a feature of where commercial competition currently sits, not where the market actually goes. $NVO $LLY

$NVO $LLY No- Dear… As a doctor invested in Novo, I am concerned that Novo’s pipeline isn’t very convincing and investors must be aware of this situation. CagriSema raises real questions. Here’s why 👇

@capitalzeph And medically? Superior too. >Less contraindications vs LLY >Less dropouts in trials vs LLY >proven MACE benefits >potential MASH benefits > we’re now seeing potential for cancer benefits & psoriasis too It’s not a drug, it’s magic 👀

@FinanceDocUK cheaper AND easier to administer... 👀👀👀

@CesFCruz Hey! So 2 possible reasons 1. What you said ^ 2. Or, Novo were extremely (over) confident that low dose would be very potent. Either way, the trial was a flop.

@FinanceDocUK The choice really left me wondering why. Maybe they were worried higher doses may have a worse safety profile?

@fdzmurillo @VSchwazkopf @Matkinvest Very true! By the time Reta is out: - Oral space would have been dominated by Novo’s Wegovy pill, and future patients seeking WL treatment will naturally choose orals Will be very interesting!